Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

导出 OA

翻译打印收藏纠错

第一作者： William R,Lumry

第一单位： Allergy Asthma Research Associates Research Center, Dallas, TX, USA.

作者： William R,Lumry ^[1] ; Karsten,Weller ^[2] ; Markus,Magerl ^[2] ; Aleena,Banerji ^[3] ; Hilary J,Longhurst ^[4] ; Marc A,Riedl ^[5] ; Hannah B,Lewis ^[6] ; Peng,Lu ^[7] ; Giovanna,Devercelli ^[7] ; Gagan,Jain ^[7] ; Marcus,Maurer ^[2] ; HELP Study Investigators

作者单位： Allergy Asthma Research Associates Research Center, Dallas, TX, USA. ^[1] Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. ^[2] Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ^[3] Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, and University College London Hospitals, London, UK. ^[4] Division of Rheumatology, Allergy & Immunology, University of California San Diego, La Jolla, CA, USA. ^[5] ICON plc, London, UK. ^[6] Takeda Pharmaceutical Company Limited, Lexington, MA, USA. ^[7]

关键词 AE-QoL hereditary angioedema lanadelumab long-term prophylaxis quality of life

主题词血管水肿, 遗传性(Angioedemas, Hereditary);人类(Humans);生活质量(Quality of Life)

DOI 10.1111/all.14680

PMID 33258114

发布时间 2022-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交